MRG003+HX008

DRUG2 trials

Sponsors

Shanghai Miracogen Inc.

Conditions

Advanced Solid TumorsRecurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Phase 1

A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

Shanghai Miracogen Inc.Advanced Solid Tumors

Start: 2022-06-30End: 2025-07-31Target: 18Updated: 2023-01-18

Phase 2

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

RecruitingNCT04868162

Shanghai Miracogen Inc.Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Start: 2021-04-23End: 2026-12-31Target: 116Updated: 2025-07-08

Related Papers

Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck: A Multicenter, Phase IIa Trial.

2026-01-28

Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors.

Journal of Clinical Oncology2024-06-018 citations